Chairs: Josep Tabernero, MD, PhD and Eric Van Cutsem, MD, PhD

Updates on CALGB/SWOG 80405: Alan P. Venook, MD

SLIDES


Discussant: When clinical trials are practice changing
Alberto Sobrero, MD 

SLIDES


SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment: Guy van Hazel, et al., O-019

SLIDES

Discussant
Dirk Arnold, MD

SLIDES


Quality-of-life results from RAISE Randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine: Rocio Garcia-Carbonero, et al., O-020

SLIDES



Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab: Fortunato Ciardiello, et al., LBA-09

SLIDES

Discussant: How to choose between the different biologics in 2nd line
Michel Ducreux, MD, PhD

SLIDES

Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC): Eric Van Cutsem et al., LBA-07

SLIDES



Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab+alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer: Elena Elez et al., LBA-08  

SLIDES

Discussant: What to do in BRAF mutant CRC patients?
Ramon Salazar Soler, MD 

SLIDES

The ESMO consensus on metastatic CRC – 2015
Eric Van Cutsem, MD, PhD, Dirk Arnold, MD, and Andrés Cervantes, MD, PhD

SLIDES